145 related articles for article (PubMed ID: 20536411)
1. SHIP2 and its involvement in various diseases.
Suwa A; Kurama T; Shimokawa T
Expert Opin Ther Targets; 2010 Jul; 14(7):727-37. PubMed ID: 20536411
[TBL] [Abstract][Full Text] [Related]
2. Lipid phosphatases as a possible therapeutic target in cases of type 2 diabetes and obesity.
Sasaoka T; Wada T; Tsuneki H
Pharmacol Ther; 2006 Dec; 112(3):799-809. PubMed ID: 16842857
[TBL] [Abstract][Full Text] [Related]
3. Endogenous SHIP2 does not localize in lipid rafts in 3T3-L1 adipocytes.
Jacobs C; Onnockx S; Vandenbroere I; Pirson I
FEBS Lett; 2004 May; 565(1-3):70-4. PubMed ID: 15135055
[TBL] [Abstract][Full Text] [Related]
4. ["SHIP2 and insulin signaling: what is its role in the pathogenesis and treatment of type 2 diabetes?"].
Schurmans S
Bull Mem Acad R Med Belg; 2003; 158(7-9):335-9; discussion 340. PubMed ID: 15132004
[TBL] [Abstract][Full Text] [Related]
5. Discovery and functional characterization of a novel small molecule inhibitor of the intracellular phosphatase, SHIP2.
Suwa A; Yamamoto T; Sawada A; Minoura K; Hosogai N; Tahara A; Kurama T; Shimokawa T; Aramori I
Br J Pharmacol; 2009 Oct; 158(3):879-87. PubMed ID: 19694723
[TBL] [Abstract][Full Text] [Related]
6. SHIP2: an emerging target for the treatment of type 2 diabetes mellitus.
Baumgartener JW
Curr Drug Targets Immune Endocr Metabol Disord; 2003 Dec; 3(4):291-8. PubMed ID: 14683460
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of SH2-containing inositol phosphatase 2 results in negative regulation of insulin-induced metabolic actions in 3T3-L1 adipocytes via its 5'-phosphatase catalytic activity.
Wada T; Sasaoka T; Funaki M; Hori H; Murakami S; Ishiki M; Haruta T; Asano T; Ogawa W; Ishihara H; Kobayashi M
Mol Cell Biol; 2001 Mar; 21(5):1633-46. PubMed ID: 11238900
[TBL] [Abstract][Full Text] [Related]
8. The SH2 domain containing inositol polyphosphate 5-phosphatase-2: SHIP2.
Dyson JM; Kong AM; Wiradjaja F; Astle MV; Gurung R; Mitchell CA
Int J Biochem Cell Biol; 2005 Nov; 37(11):2260-5. PubMed ID: 15964236
[TBL] [Abstract][Full Text] [Related]
9. Normalization of prandial blood glucose and improvement of glucose tolerance by liver-specific inhibition of SH2 domain containing inositol phosphatase 2 (SHIP2) in diabetic KKAy mice: SHIP2 inhibition causes insulin-mimetic effects on glycogen metabolism, gluconeogenesis, and glycolysis.
Grempler R; Zibrova D; Schoelch C; van Marle A; Rippmann JF; Redemann N
Diabetes; 2007 Sep; 56(9):2235-41. PubMed ID: 17596404
[TBL] [Abstract][Full Text] [Related]
10. The inositol phosphatase SHIP2 negatively regulates insulin/IGF-I actions implicated in neuroprotection and memory function in mouse brain.
Soeda Y; Tsuneki H; Muranaka H; Mori N; Hosoh S; Ichihara Y; Kagawa S; Wang X; Toyooka N; Takamura Y; Uwano T; Nishijo H; Wada T; Sasaoka T
Mol Endocrinol; 2010 Oct; 24(10):1965-77. PubMed ID: 20829391
[TBL] [Abstract][Full Text] [Related]
11. Dual role of SRC homology domain 2-containing inositol phosphatase 2 in the regulation of platelet-derived growth factor and insulin-like growth factor I signaling in rat vascular smooth muscle cells.
Sasaoka T; Kikuchi K; Wada T; Sato A; Hori H; Murakami S; Fukui K; Ishihara H; Aota R; Kimura I; Kobayashi M
Endocrinology; 2003 Sep; 144(9):4204-14. PubMed ID: 12933696
[TBL] [Abstract][Full Text] [Related]
12. SH2-containing inositol 5-phosphatases 1 and 2 in blood platelets: their interactions and roles in the control of phosphatidylinositol 3,4,5-trisphosphate levels.
Giuriato S; Pesesse X; Bodin S; Sasaki T; Viala C; Marion E; Penninger J; Schurmans S; Erneux C; Payrastre B
Biochem J; 2003 Nov; 376(Pt 1):199-207. PubMed ID: 12885297
[TBL] [Abstract][Full Text] [Related]
13. A synthetic polyphosphoinositide headgroup surrogate in complex with SHIP2 provides a rationale for drug discovery.
Mills SJ; Persson C; Cozier G; Thomas MP; Trésaugues L; Erneux C; Riley AM; Nordlund P; Potter BV
ACS Chem Biol; 2012 May; 7(5):822-8. PubMed ID: 22330088
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional profiling of C2C12 myotubes in response to SHIP2 depletion and insulin stimulation.
Huard C; Martinez RV; Ross C; Johnson JW; Zhong W; Hill AA; Kim R; Paulsen JE; Shih HH
Genomics; 2007 Feb; 89(2):270-9. PubMed ID: 17123777
[TBL] [Abstract][Full Text] [Related]
15. SH2-containing inositol phosphatase 2 negatively regulates insulin-induced glycogen synthesis in L6 myotubes.
Sasaoka T; Hori H; Wada T; Ishiki M; Haruta T; Ishihara H; Kobayashi M
Diabetologia; 2001 Oct; 44(10):1258-67. PubMed ID: 11692174
[TBL] [Abstract][Full Text] [Related]
16. Glucose metabolism activation by SHIP2 inhibitors via up-regulation of GLUT1 gene in L6 myotubes.
Suwa A; Kurama T; Yamamoto T; Sawada A; Shimokawa T; Aramori I
Eur J Pharmacol; 2010 Sep; 642(1-3):177-82. PubMed ID: 20558154
[TBL] [Abstract][Full Text] [Related]
17. The lipid phosphatase SHIP2 controls insulin sensitivity.
Clément S; Krause U; Desmedt F; Tanti JF; Behrends J; Pesesse X; Sasaki T; Penninger J; Doherty M; Malaisse W; Dumont JE; Le Marchand-Brustel Y; Erneux C; Hue L; Schurmans S
Nature; 2001 Jan; 409(6816):92-7. PubMed ID: 11343120
[TBL] [Abstract][Full Text] [Related]
18. The association between the SH2-containing inositol polyphosphate 5-Phosphatase 2 (SHIP2) and the adaptor protein APS has an impact on biochemical properties of both partners.
Onnockx S; De Schutter J; Blockmans M; Xie J; Jacobs C; Vanderwinden JM; Erneux C; Pirson I
J Cell Physiol; 2008 Jan; 214(1):260-72. PubMed ID: 17620296
[TBL] [Abstract][Full Text] [Related]
19. PTEN and SHIP2 phosphoinositide phosphatases as negative regulators of insulin signalling.
Vinciguerra M; Foti M
Arch Physiol Biochem; 2006 Apr; 112(2):89-104. PubMed ID: 16931451
[TBL] [Abstract][Full Text] [Related]
20. SH2-containing inositol 5'-phosphatase 2 selectively impairs hypothalamic insulin signalling and regulation of food intake in mice.
Ichihara Y; Wada T; Soeda Y; Ishii Y; Sasahara M; Tsuneki H; Sasaoka T
J Neuroendocrinol; 2013 Apr; 25(4):372-82. PubMed ID: 23286299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
